UAS regulatory sequences drive expression of a mutant form of Pka-R1 that contains a mutation in a cAMP binding site (amino acid replacement G321D). This mutant regulatory subunit acts as an inhibitor of protein kinase A (PKA) activity; although the subunit can be activated in vitro by cAMP, it requires cAMP concentrations higher than those likely to be seen in vivo.